This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer; ophthalmic disease	Ets variant 6 (ETV6; TEL)	<i>In vitro</i> and zebrafish studies suggest that inhibiting TEL could help treat pathogenic angiogenesis. In a primary human cell assay, vector expression of anti-TEL small hairpin RNA prevented endothelial cell sprouting and upregulated genes that inhibit angiogenesis compared with control shRNA expression. In zebrafish embryos, morpholino oligonucleotides targeting TEL prevented vessel formation during early embryogenesis compared with control morpholino oligonucleotides. Next steps include further target validation and development of a therapeutic candidate.	Patent application filed for medical use of the target; available for licensing	Roukens, M. <i>et al. Nat. Cell Biol.</i> ; published online Sept. 12, 2010; doi:10.1038/ncb2096 Contact: David A. Baker, Leiden University Medical Center, Leiden, the Netherlands e-mail: d.baker@lumc.nl
SciBX 3(36); doi:10.1038/scibx.2010.1087 Published online Sept. 16, 2010				